Kiniksa Pharmaceuticals International, plc $KNSA Stock Sold by Penn Capital Management Company LLC

Penn Capital Management Company LLC reduced its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 5.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 347,664 shares of the company’s stock after selling 20,450 shares during the period. Kiniksa Pharmaceuticals International accounts for approximately 1.9% of Penn Capital Management Company LLC’s investment portfolio, making the stock its 4th largest holding. Penn Capital Management Company LLC’s holdings in Kiniksa Pharmaceuticals International were worth $25,967,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Allworth Financial LP lifted its holdings in shares of Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after purchasing an additional 134 shares in the last quarter. Arizona State Retirement System raised its position in shares of Kiniksa Pharmaceuticals International by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after purchasing an additional 209 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Kiniksa Pharmaceuticals International by 21.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock worth $95,000 after purchasing an additional 223 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after purchasing an additional 237 shares during the last quarter. Finally, First Trust Advisors LP raised its position in shares of Kiniksa Pharmaceuticals International by 3.1% during the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after purchasing an additional 293 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock opened at $98.76 on Tuesday. The firm has a market cap of $7.71 billion, a P/E ratio of 75.97 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 1-year low of $37.02 and a 1-year high of $99.31. The firm’s 50-day simple moving average is $80.87 and its 200-day simple moving average is $61.65.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. Analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider John Paolini sold 77,587 shares of the stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $93.02, for a total transaction of $7,217,142.74. Following the transaction, the insider owned 69,922 shares of the company’s stock, valued at $6,504,144.44. This trade represents a 52.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael Megna sold 36,260 shares of Kiniksa Pharmaceuticals International stock in a transaction on Friday, October 30th. The shares were sold at an average price of $94.43, for a total transaction of $3,424,031.80. Following the completion of the transaction, the chief accounting officer owned 12,697 shares in the company, valued at approximately $1,198,977.71. This trade represents a 74.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 831,022 shares of company stock valued at $77,475,599 over the last 90 days. 51.98% of the stock is currently owned by insiders.

Analyst Ratings Changes

KNSA has been the topic of a number of recent research reports. Wedbush upped their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a research note on Wednesday, October 28th. JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Wells Fargo & Company upped their price objective on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Finally, The Goldman Sachs Group increased their price objective on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally.

Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

The company also develops investigational therapies for inflammatory and immune-mediated conditions, including treatments that target pathways involved in immune-cell activity.